Abstract:Future VirologyVol. 8, No. 1 EditorialFree AccessDevelopment of SARS vaccines and therapeutics is still neededShibo Jiang, Lu Lu & Lanying DuShibo Jiang* Author for correspondenceKey Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China. Search for more papers by this authorEmail the corresponding author at shibojiang@fudan.edu.cn, Lu LuKey Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, ChinaSearch for more papers by this author & Lanying DuThe Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10065, USASearch for more papers by this authorPublished Online:20 Dec 2012https://doi.org/10.2217/fvl.12.126AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: HCoV-EMChuman coronavirusreceptor-binding domainSARSSARS-CoVspike proteintherapeuticsvaccinesOn 22 September 2012, the WHO was informed by the UK of a case of acute respiratory syndrome with renal failure [101]. The patient had a travel history to the Kingdom of Saudi Arabia, where a 60 year-old Saudi national died from a similar disease earlier in 2012. The causative pathogen, a novel human Betacoronavirus (HCoV-EMC), was quickly identified from the sputum samples of the earlier case [1] and the gene sequence of this virus was 99.5% identical to that of the virus isolated from clinical samples of the later case.The outbreak of HCoV-EMC infection in Saudi Arabia has raised great concerns about the potential pandemic of the SARS-like disease, and strategies for combating this newly emerged infectious disease should be prepared [2]. It is believed that the existing SARS research may provide a useful template for developing vaccines and therapeutics against HCoV-EMC infection [3], but so far, no effective anti-SARS vaccines and therapeutics have been well developed.SARS, which is caused by the SARS coronavirus (SARS-CoV), emerged from China and caused nearly 8500 cases and 916 deaths during the outbreak in 2002 and 2003 [3–5]. Although SARS is currently under control, the possibility of a new SARS outbreak remains a global concern because of the potential for zoonotic transmission of SARS-CoV or SARS-CoV-like viruses from their natural hosts to humans, or the accidental or intentional release of laboratory SARS-CoV strains [6]. Therefore, developing vaccines and therapeutics for the prevention and treatment of SARS is still a matter of urgency.During the global 2002/2003 SARS pandemic, many foundations, pharmaceutical companies and governments provided abundant funds to support the development of anti-SARS vaccines and therapeutics. However, after the disappearance of SARS, these funds were either withdrawn or discontinued because of the lack of a sustainable market of the products to be developed.A number of inactivated and live-attenuated SARS vaccines, as well as those based on vectors encoding the full-length S protein of SARS-CoV, showed high immunogenicity in inducing neutralizing antibody responses and protection against SARS-CoV challenge [6]. However, most of these vaccine candidates may also induce immunopathology or other harmful immune responses [7,8], raising concerns about their safety. On the other hand, recombinant proteins containing the receptor-binding domain of the SARS-CoV S protein could be developed as a safe and effective SARS vaccine. This potential is based on the ability of receptor binding domain-based vaccine to induce stronger cross-neutralizing antibody responses and protection against SARS-CoV [9], with a correspondingly lower probability of inducing immunopathology, in contrast with the other SARS vaccine candidates mentioned previously [6].So far, no specific anti-SARS drugs have been developed. A number of drug candidates, including the SARS-CoV fusion inhibitors [10], proteinase (e.g., 3C-like cysteine proteinase) inhibitors, PLpro inhibitors, RNA-dependent RNA polymerase inhibitors, helicase inhibitors, siRNAs inhibiting SARS-CoV structural proteins E, M and N, and therapeutic antibodies, have been developed in laboratory and preclinical studies [11]. However, none of them have been forwarded to clinical trials, possibly for the same reasons as previously described for vaccine development.Apart from financial support, another main challenge for the clinical development of anti-SARS vaccines is the lack of endemic SARS and the lethal nature of the disease. It is not ethical to conduct human efficacy studies by exposing healthy human volunteers to a lethal agent like SARS-CoV. Fortunately, however, according to the ‘Animal Rule’, a pivotal animal efficacy study can be conducted for evaluating the in vivo efficacy of the anti-SARS vaccines using two animal species that exhibit pathophysiology of the disease and host immune responses that closely match those of humans [12]. The data from these animal experiments can then be considered by the US FDA as evidence of effectiveness of the tested vaccine.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.References1 Zaki AM, van Boheemen S, Bestebroer TM et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med.367(19),1814–1820 (2012).Crossref, Medline, CAS, Google Scholar2 Anderson LJ, Baric RS. Emerging human coronaviruses: disease potential and preparedness. N. Engl. J. Med.367(19),1850–1852 (2012).Crossref, Medline, CAS, Google Scholar3 Butler D. SARS veterans tackle coronavirus. Nature490(7418),20 (2012).Crossref, Medline, CAS, Google Scholar4 Zhong NS, Zheng BJ, Li YM et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet362(9393),1353–1358 (2003).Crossref, Medline, CAS, Google Scholar5 Peiris JSM, Lai ST, Poon LLM et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet361(9366),1319–1325 (2003).Crossref, Medline, CAS, Google Scholar6 Du L, He Y, Zhou Y et al. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat. Rev. Microbiol.7(3),226–236 (2009).Crossref, Medline, CAS, Google Scholar7 Weingartl H, Czub M, Czub S et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol.78(22),12672–12676 (2004).Crossref, Medline, CAS, Google Scholar8 Tseng CT, Sbrana E, Iwata-Yoshikawa N et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One7(4),e35421 (2012).Crossref, Medline, CAS, Google Scholar9 He Y, Li J, Li W et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol.176(10),6085–6092 (2006).Crossref, Medline, CAS, Google Scholar10 Liu S, Xiao G, Chen Y et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet363(9413),938–947 (2004).Crossref, Medline, CAS, Google Scholar11 Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol.6(5),615–631 (2011).Link, Google Scholar12 Burns DL. Licensure of vaccines using the animal rule. Curr. Opin. Virol.2(3),353–356 (2012).Crossref, Medline, Google Scholar101 WHO. Global Alert and Response. www.who.int/csr/don/2012_09_23/en/index.htmlGoogle ScholarFiguresReferencesRelatedDetailsCited ByImmunogenicity of a secreted, C-terminally truncated, form of bovine viral diarrhea virus E2 glycoprotein as a potential candidate in subunit vaccine development6 January 2023 | Scientific Reports, Vol. 13, No. 1Immune Response to SARS-CoV-2 Vaccines21 June 2022 | Biomedicines, Vol. 10, No. 7The Coronavirus pandemic – 2022: Viruses, variants & vaccinesCytokine & Growth Factor Reviews, Vol. 63Coronavirus (SARS-CoV-2): a systematic review for potential vaccines5 February 2021 | Human Vaccines & Immunotherapeutics, Vol. 18, No. 1Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19Journal of Infection and Public Health, Vol. 14, No. 8Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses28 May 2021 | Frontiers in Immunology, Vol. 12Surging publications on the COVID-19 pandemicClinical Microbiology and Infection, Vol. 27, No. 3Revisiting potential druggable targets against SARS‐CoV ‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review6 July 2020 | Drug Development Research, Vol. 81, No. 8Adjuvants for Coronavirus Vaccines6 November 2020 | Frontiers in Immunology, Vol. 11Potential strategies for combating COVID-1910 August 2020 | Archives of Virology, Vol. 165, No. 11COVID-19 (An International Trauma): A Brief Analysis on Research Trends, Impacts and Solutions11 April 2020 | International Journal For Research in Applied Sciences and Biotechnology, Vol. 07, No. 02Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatmentJournal of Research in Medical Sciences, Vol. 25, No. 1Demonstration Study: A Protocol to Combine Online Tools and Databases for Identifying Potentially Repurposable Drugs4 May 2017 | Data, Vol. 2, No. 2Environmental risks in a diffusive SIS model incorporating use efficiency of the medical resourceDiscrete and Continuous Dynamical Systems - Series B, Vol. 21, No. 5Cell adhesion as a novel approach to determining the cellular binding motif on the severe acute respiratory syndrome coronavirus spike proteinJournal of Virological Methods, Vol. 201 Vol. 8, No. 1 STAY CONNECTED Metrics History Published online 20 December 2012 Published in print January 2013 Information© Future Medicine LtdKeywordsHCoV-EMChuman coronavirusreceptor-binding domainSARSSARS-CoVspike proteintherapeuticsvaccinesFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download

Abstract:At the end of 2019, a new coronavirus disease (COVID-19) emerged in Wuhan city, Hubei Province, China, which has quickly spread to the whole of China and more than 20 countries.[1–4] This disease results from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the family Coronaviridae.[5] It is likely that wild animals serve as the reservoir host of SARS-CoV-2 and that transmission to humans occurred via wildlife trading[4,6]; however, the natural host of this novel coronavirus remains unknown. The challenges to stopping this epidemic need to be dissected and further strategies should be explored. Sporadic outbreaks may continue Although epidemics wane over time, sporadic outbreaks of case clusters may continue. As identification of the natural host of SARS-CoV-2 remains elusive, transmission from the natural host to humans may occur via occasional contact.[2] As wildlife trading has been prohibited in China, such transmission will be greatly diminished; however, occasional contact may trigger an outbreak of cases.[7] Identifying a natural host is critical for the final control of this disease, which requires enormous and continued effort. Transmission from cases of latent and silent virus infection has fueled the challenges. It has recently been reported that transmission could occur during latent infection. A father and daughter with a travel history to Wuhan returned to their hometown; although neither showed symptoms, members of their family developed COVID-19, suggesting that transmission could occur from silent infection.[7,8] The occurrence of transmission from an unknown natural host and possibly from latent and silent infections pose great challenges to disrupting the chain of infection and thereby terminating this epidemic. Vaccine against SARS-CoV-2 is the best approach to stop the epidemic A vaccine is composed of, at minimum, an immunogen and an adjuvant.[9] The immunogen comprises features of a potential invading pathogen and thereby serves as the target for immune responses. Adjuvant regulates the strength of the immune response, meaning how vigorously the immune system attacks the target. Inactivated virus vaccine As the threat from SARS-CoV-2 will likely continue, it is urgent to develop an effective vaccine. A traditional inactivated vaccine could be rapidly developed as vaccine development technologies have matured and production facilities are well established.[10–12] However, the risk of residual virus infectivity remains a consideration, and over-inactivation may be implemented for safety reasons, as in the diphtheria-tetanus vaccine.[13,14] Because the virus conformational structure is usually sensitive to the inactivation process, over-inactivation may destroy the conformational neutralizing epitopes and result in the induction of only marginal—or even failure to induce—neutralizing antibody responses by the inactivated vaccine. Therefore, it is reasonable to develop a vaccine using alternative approaches. Nucleic acid vaccines The great advantages of DNA-[15] and RNA-[16] based vaccines lie in the possibility of rapid early development and effective tools to screen protective immunogens. As construction of a DNA/RNA vaccine takes only weeks, it is possible to surpass development of an inactivated vaccine that is in early development, in a manner that is even more efficient. However, the high cost of producing and delivering these vaccines as well as the problem of low immunogenicity dampens enthusiasm to scale up production capacity for DNA and RNA vaccines.[17,18] However, it is worth exploring the use of these vaccines as a screening tool to identify and optimize immunogens. In addition, DNA vaccines may function as good primers to concentrate host immune responses on the viral-derived immunogen and help to improve the efficacy of a subsequent boost immunization.[19] Whereas it is unlikely a DNA/RNA vaccine alone could be used against SARS-CoV-2, it would be very useful to merge this tool with the overall vaccine development strategies. Subunit protein/nanoparticle vaccines Since the success of the HBV subunit protein vaccine in the 1980s,[20] subunit vaccines have been considered to have enhanced safety but less effectiveness. To further improve the efficacy of subunit protein vaccines, different adjuvants have been developed and incorporated into immunization formulations, including AS02, MF59, and CpG.[21,22] Nanoparticle vaccines have been tested for many years since introduction of the uman papillomavirus vaccine, which uses virus-like nanoparticles assembled from different genotypes.[23,24] As the high immunogenicity of these virus-like particles is very attractive for vaccine development, researchers have tried to apply a similar strategy in the development of vaccines against membraned viruses, which are unable to assemble virus-like particles, such as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).[25,26] The auto-assembling capacity of ferritin into nanoparticles has been explored in vaccine development against membraned viruses. By fusing virus-derived immunogens with ferritin, the chimeric proteins could assemble into nanoparticles as an immunogenic vaccine. Adjuvant molecules may be further incorporated into the nanoparticles to enhance immunogenicity. A nanoparticle-based vaccine against SARS-CoV-2 would have enhanced safety and efficacy, but would likely involve a prolonged development process. Viral/bacterial vectored vaccines Vectored vaccines were introduced in the mid-1990s[27] and have been extensively used in vaccine development in the United States and Europe. However, this area remains undeveloped in China for human vaccines, although the potential future use of this category vaccine in humans is likely. Use of vectored vaccines is the most effective approach to elicit vigorous T-cell responses, which confers the advantage of being capable of protect against a broader spectrum of pathogens[28,29]; thus, vectored vaccines have an indispensable role in development of a universal vaccine. In this regard, a universal vaccine against coronaviruses, such as SARS-CoV, MERS-CoV, and Bat-CoV, will probably include the vectored vaccine in a vaccination regimen. Human-derived cell-based vaccines The expression of hemagglutinin protein by influenza viruses,[30] the envelope glycoprotein by human immunodeficiency virus-1,[31] or spike protein by SARS-CoV[31] on the virus membrane can elicit neutralizing antibody responses. As is known, the viral membrane is derived from the host cell membrane[32]; therefore, expression of these proteins on human-derived cell membranes can induce neutralizing antibodies. By expressing spike protein on a human cell membrane, human-derived cells could be used in a vaccine. As these protein-expressing human cells do not contain other viral proteins, such vaccines would be safer than virus vaccines, which include the entire set of viral proteins. Indeed, a human cell-based vaccine could also be subjected to an inactivation process, such as via X-ray, heat, or chemical inactivation. Interestingly, X-ray-based inactivation mainly destroys the nuclear DNA and retains the structure of membrane protein, thereby protecting conformational neutralizing epitopes from damage and ensuring the vaccine's capacity to mount good neutralizing antibody responses. Challenges in vaccine development Although there is consensus that development of an effective vaccine is urgent, challenges exist in both research and development as well as policies aiming to establish precautionary, preparatory steps in the development and use of a vaccine against SARS-CoV-2. Antibody-dependent enhancement It has been observed that rather than protecting host cells from a pathogen attack, antibodies may also mediate enhanced pathogenesis, a phenomenon known as antibody-dependent enhancement (ADE).[33] ADE has been reported in SARS-associated viruses,[34,35] dengue viruses,[34,35] and hand-foot-mouth disease viruses.[36] The underlying mechanism may originate from fragment crystallizable (Fc) receptor-mediated activation of macrophages. In addition to neutralizing antibodies blocking viral binding to receptors to protect host cells, non-neutralizing antibody binding to its epitope on the virus surface could direct the antigen–antibody complex to Fc receptor-positive cells (such as macrophages) via the antibody's Fc domain.[37] This process will activate macrophages to produce inflammatory cytokines, resulting in immune pathogenesis. As macrophage cells are distributed all over the body, inflammation may occur in different organs and could cause organ failure. It is known that the interaction between T cells and macrophages could calm the inflammatory response; however, the exhaustion of T cells may enable macrophages to launch an enhanced inflammatory response. Indeed, one-third of patients with COVID-19 are characterized by T-cell exhaustion.[38–41] It has been noted that non-receptor binding domain (RBD)-specific antibodies represent the main resource for ADE; it would therefore be optimal to use RBDs as vaccine immunogen to reduce the potential for ADE. However, it remains unknown whether the RBD alone would be sufficient to elicit neutralizing antibodies. Difficulty with a SARS-CoV-2 animal challenge model An animal infection model is under development. ACE2 transgenic mice have been developed, but more time and expanded facilities are needed, problems that are unlikely to be resolved soon. In addition, according to regulations, this challenge should be implemented in an animal biosafety level 3 (BSL-3) facility, only a few of which are available. Moreover, live strains of SARS-CoV-2 have only been successfully isolated in a limited number of laboratories.[4] Therefore, it is very difficult to bring together all the elements required for an animal challenge model. Similar challenges exist for a non-human primate model, which requires a large-animal BSL-3 facility. In the near future, competition for access to such animal facilities will be a great challenge in vaccine development. Alternative surrogates should be considered, such as neutralization in vitro assays, which could greatly augment vaccine development. The neutralization antibody titers against RBD and the ratio of antibody responses targeting RBD to the whole S protein may be considered as good surrogates. Policy challenges to clinical trials For safety considerations, vaccine development must go through a long, complex process, from early development to marketing of a vaccine. It is likely this will remain the case for development of a SARS-CoV-2 vaccine. How to speed up this process while maintaining safety will be an important issue to resolve. As proposed above, alternative surrogates for protection against SARS-CoV-2 should be included as part of the guidelines for vaccine development. In addition, if no severe side-effects are observed in primate immunization, a phase 0 trial could be approved, which may greatly encourage innovation and stimulate the field of new vaccine development. Acknowledgments None. Author contributions The author wrote the manuscript and approved the final version of the manuscript. Financial support None. Conflicts of interest The author has no conflicts of interest to declare.

SARS Vaccine Development

Vaccine design for severe acute respiratory syndrome coronavirus.

Development of Subunit Vaccines Against Severe Acute Respiratory Syndrome.

Receptor-binding Domain As a Target for Developing SARS Vaccines.

Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.

Development of SARS Vaccines and Therapeutics is Still Needed

A Single Dose SARS-CoV-2 Simulating Particle Vaccine Induces Potent Neutralizing Activities

561. Recombinant Adenovirus Carrying Spike Gene Induces Effective Humoral and Cellular Immunity Against SARS-CoV in Rats

Immunogenicity and Protective Efficacy in Monkeys of Purified Inactivated Vero-Cell Sars Vaccine

SARS Immunity and Vaccination.

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection.

Yeast-expressed Recombinant Protein of the Receptor-Binding Domain in SARS-CoV Spike Protein with Deglycosylated Forms As a SARS Vaccine Candidate

A 219-Mer Cho-Expressing Receptor-Binding Domain of Sars-Cov S Protein Induces Potent Immune Responses and Protective Immunity

Protective Humoral Responses to Severe Acute Respiratory Syndrome-Associated Coronavirus: Implications for the Design of an Effective Protein-Based Vaccine.

SARS-CoV-2: an Unknown Agent and Challenges in Vaccine Development

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity

Identification of a Critical Neutralization Determinant of Severe Acute Respiratory Syndrome (Sars)-Associated Coronavirus: Importance for Designing SARS Vaccines.

Construction of a Eukaryotic Expression Plasmid Encoding Partial S Gene Fragments of the SARS-CoV and Its Potential Utility As a DNA Vaccine

Recombinant Receptor-Binding Domain of SARS-CoV Spike Protein Expressed in Mammalian, Insect and E. Coli Cells Elicits Potent Neutralizing Antibody and Protective Immunity